Welcome to our dedicated page for Patient Access news (Ticker: PASO), a resource for investors and traders seeking the latest updates and insights on Patient Access stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Patient Access's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Patient Access's position in the market.
Patient Access Solutions, Inc. (PASO) has launched the CAMEO™ program to address the critical issues in the mental healthcare industry. With over 100 million individuals suffering from treatment-resistant depression globally, the program aims to improve access and affordability of care. CAMEO™ offers a network of mental health professionals through Telamentalhealth.com and provides treatment options, including Trans Cranial Magnetic Stimulation and IV therapy. The initiative seeks to alleviate the pressures on the current healthcare system by delivering both traditional and innovative mental health solutions.
Patient Access Solutions, Inc. (PASO) announced a partnership with Veterans for America First (VFAF) and Telamentalhealth.com to provide unlimited 24/7 mental health visits for veterans at a monthly cost of $29.95. This initiative supports veterans with anxiety and depression, offering services such as immediate crisis support, educational resources, and counseling without co-pays. The program aims to reduce veteran suicides by making mental health care accessible to nearly 400,000 veterans. Additional therapies like TMS and Ketamine will be available at the new location in New Hyde Park, NY.
Patient Access Solutions (PASO) announces the opening of a new Medical Center in New Hyde Park, NY, effective August 2, 2021. This new facility aligns with the company’s growth strategy, supported by their recent acquisition of telamentalhealth.com. Expected to generate over $5 million in sales within its first year, the Center will focus on treating anxiety, depression, PTSD, and related conditions using innovative therapies, including Ketamine therapy. The company aims to establish the Center as a leader in neuro informatics and excellence in care.
Patient Access Solutions (PASO) has announced its acquisition of Tela Mental Health LLC, enhancing its portfolio by providing mental health services through the telamentalhealth.com platform. This strategic move aims to offer unlimited access to mental health professionals for a low monthly fee of $29.95, serving patients and their families. The company targets over 10,000 subscribers in the first six months, capitalizing on the increasing demand for telemedicine. This acquisition positions PASO to meet the needs of the growing population experiencing mental health challenges, particularly post-COVID-19.
Patient Access Solutions, Inc. (PASO) is set to manage a new Medical Center in New Hyde Park, NY, focusing on advanced mental health solutions. This facility will offer Ketamine therapy for anxiety and depression, targeting patients with treatment-resistant conditions. Programs will consist of 6-9 sessions, costing approximately $4,000, with some potential for reimbursement. PASO aims to establish credibility through partnerships with leading Ketamine Therapy Clinics. The Center will also incorporate innovative technologies to address various mental health issues, aiming to become a leader in the growing NY market.
Patient Access Solutions, Inc. (OTC PINK: PASO) has announced a partnership with Hestia Insight and US Stem Cell to form a consortium aimed at treating anxiety and depression. These conditions significantly impact millions in the U.S., with over 40 million adults affected by anxiety and around 19 million by depression. The consortium will utilize Transcranial Magnetic Stimulation (TMS) to enhance brain function. This initiative aligns with a growing healthcare market, projected to reach $11,909 billion by 2022, reflecting a CAGR of 8.9%.
Patient Access Solutions, Inc. (PASO) announced a consortium with Hestia Insight and US Stem Cell to address anxiety and depression through innovative treatments. Anxiety affects 40 million adults in the U.S., while depressive disorders impact 19 million. The consortium will use Trancranial Magnetic Stimulation (TMS) to improve treatment outcomes for these coexisting disorders. The initiative aims to provide facility locations, funding, patient awareness campaigns, and billing. The global healthcare market is projected to grow from $8,452 billion in 2018 to nearly $11,909 billion by 2022.
FAQ
What is the current stock price of Patient Access (PASO)?
What is the market cap of Patient Access (PASO)?
